Tech Company Financing Transactions
Boston Immune Technologies and Therapeutics Funding Round
Boston Immune Technologies and Therapeutics closed a $10 million Series A funding round on 3/18/2021. Backers included BeiGene, EGP Investments and Hatteras Venture Partners.
Transaction Overview
Company Name
Announced On
3/18/2021
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Proceeds Purpose
Funds will support the clinical development of BIR2101, a novel, TNFR2 antagonist antibody for indications in oncology and infectious disease and additional pipeline candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
81 Walnut St.
Winchester, MA 01890
USA
Winchester, MA 01890
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Boston Immune Technologies and Therapeutics (BITT) is a Boston, MA based company developing a novel class of antagonist antibodies targeting the TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Russell LaMontagne
Chief Medical Officer
Samson Fung
VP - Finance
Elena Ende
VP - General Counsel
Steve Andress
Browse more venture capital transactions:
Prev: 3/17/2021: HeraSoft venture capital transaction
Next: 3/18/2021: Happify venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs